Results 111 to 120 of about 1,330 (154)
Safety of Andexanet Alfa Use in Cardiac Surgery [PDF]
Journal of Cardiothoracic and Vascular Anesthesia, 2023 Jiapeng Huang +7 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Andexanet alfa for the treatment of hemorrhage
Expert Review of Hematology, 2018While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians.
Andrea, Cervi, Mark, Crowther
openaire +2 more sources
Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Andexanet Alfa (Andexxa) Formulary Review
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2019Andexanet alfa, a recombinant modified human “decoy” factor Xa (FXa) protein, is the first and only available antidote approved by the Food and Drug Administration to manage life-threatening or uncontrolled bleeding associated with the anti-Xa agents.
Nahal, Beik +6 more
openaire +2 more sources
Andexanet Alfa for Reversing Factor Xa Inhibition
Cardiology in Review, 2019The direct oral anticoagulants (DOACs) have gained popularity recently among both patients and providers for their comparable or better efficacy and safety profiles compared with warfarin and the lack of need for routine monitoring of anticoagulant effect. One obstacle for the more widespread use of the DOACs in clinical practice has been the lack of a
Alexandra M, Sible, James J, Nawarskas
openaire +2 more sources
In Brief: Andexanet alfa (Andexxa) Withdrawn
The Medical Letter on Drugs and TherapeuticsAndexanet alfa (Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto), has voluntarily been withdrawn from the market.1 Andexxa was the only drug FDA-approved for this indication in the US.
openaire +2 more sources